



OPEN ACCESS

EDITED AND REVIEWED BY
Tong-Chuan He,
University of Chicago Medicine, United States

*CORRESPONDENCE

Silvia La Monica

✉ silvia.lamonica@unipr.it

Andrea Cavazzoni

✉ andrea.cavazzoni@unipr.it

[†]These authors have contributed equally to this work

RECEIVED 21 November 2024

ACCEPTED 26 November 2024

PUBLISHED 06 December 2024

CITATION

Digiaco G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R and Petronini PG (2024) Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. *Front. Oncol.* 14:1532291. doi: 10.3389/fonc.2024.1532291

COPYRIGHT

© 2024 Digiaco, Fumarola, La Monica, Bonelli, Cavazzoni, Galetti, Terenziani, Eltayeb, Volta, Zoppi, Bertolini, Missale, Alfieri and Petronini. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

Graziana Digiaco^{1†}, Claudia Fumarola^{1†}, Silvia La Monica^{1*}, Mara Bonelli¹, Andrea Cavazzoni^{1*}, Maricla Galetti², Rita Terenziani¹, Kamal Eltayeb¹, Francesco Volta¹, Silvia Zoppi¹, Patrizia Bertolini³, Gabriele Missale^{1,4}, Roberta Alfieri¹ and Pier Giorgio Petronini¹

¹Department of Medicine and Surgery, University of Parma, Parma, Italy, ²Department of Occupational and Environmental Medicine, Epidemiology and Hygiene, INAIL - Italian Workers' Compensation Authority, Rome, Italy, ³Paediatric Hematology Oncology Unit, University Hospital of Parma, Parma, Italy, ⁴Unit of Infectious Diseases and Hepatology, University Hospital of Parma, Parma, Italy

KEYWORDS

hepatocarcinoma (HCC), CDK4/6 inhibition, abemaciclib, lenvatinib, senescence

A Corrigendum on

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

By Digiaco G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R and Petronini PG (2022). *Front. Oncol.* 12:942341. doi: 10.3389/fonc.2022.942341

In the published article, there was an error in **Figures 2B** and **3D** as published. Two representative images of colony formation were unintentionally inserted twice during the figure assembly for the manuscript preparation. The images of HepG2 cells shown in **Figure 3D** were inserted by mistake in **Figure 2B** (panel HepG2 cells). The images of HUH7 shown in **Figure 2B** were inserted by mistake in **Figure 3D** (panel SNU398 cells). The corrected **Figure 2B** and **Figure 3D** and their caption appear below.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.




FIGURE 2 Abemaciclib and lenvatinib combination exerts additive anti-proliferative effects in HCC cells and inhibits colony formation more strongly than single agents. **(A)** Cells were treated with A, L or the combination. The growth medium with drugs was refreshed every 3 days. After 6 days, cell proliferation was assessed by CV assay. Combination indexes were calculated with Calcsyn software. **(B)** HUH7, SNU398, and HepG2 cells were treated with A or L at their corresponding IC₅₀ values alone or in combination. After 6 days, colony formation was assessed by CV assay. Representative images of crystal violet staining of colonies are shown. ***p<0.001 vs C, ###p<0.001 vs A, §§p<0.01, §§§p<0.001 vs L. Data in A are representative of three independent experiments. Data in B are mean values ± SD of three independent experiments.




FIGURE 3

Ribociclib and lenvatinib combination exerts additive anti-proliferative effects in HCC cells and inhibits colony formation more strongly than single agents. **(A)** After 24h from seeding, HUH7, SNU398, and HepG2 cells were treated with increasing concentrations of ribociclib (R) for 6 days. Cells proliferation was evaluated by CV assay and the IC₅₀ values were calculated using GraphPad Prism 6.00 software. **(B)** HCC cells were untreated (C) or treated with 1 μM R for 24h. The cells were lysed and the expression of the indicated proteins was evaluated by Western blot analysis. **(C)** Cells were treated with R, L or the combination. The growth medium with drugs was refreshed every 3 days. After 6 days, cell proliferation was assessed by CV assay. Combination indexes were calculated with Calcsyn software. **(D)** HUH7, SNU398, and HepG2 cells were treated with R or L at their corresponding IC₅₀ values alone or in combination. After 6 days, colony formation was assessed by CV assay. Representative images of crystal violet staining of colonies are shown. ***p<0.001 vs C; #p<0.05, ##p<0.01, ###p<0.001 vs R; §p<0.05, §§p<0.001 vs L. Data in A are mean values ± SD of three independent experiments. Data in B-C are representative of two independent experiments. Data in D are mean values ± SD of two independent experiments.